Correlation Between MAIA Biotechnology and Cadrenal Therapeutics,

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both MAIA Biotechnology and Cadrenal Therapeutics, at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining MAIA Biotechnology and Cadrenal Therapeutics, into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between MAIA Biotechnology and Cadrenal Therapeutics, Common, you can compare the effects of market volatilities on MAIA Biotechnology and Cadrenal Therapeutics, and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in MAIA Biotechnology with a short position of Cadrenal Therapeutics,. Check out your portfolio center. Please also check ongoing floating volatility patterns of MAIA Biotechnology and Cadrenal Therapeutics,.

Diversification Opportunities for MAIA Biotechnology and Cadrenal Therapeutics,

-0.39
  Correlation Coefficient

Very good diversification

The 3 months correlation between MAIA and Cadrenal is -0.39. Overlapping area represents the amount of risk that can be diversified away by holding MAIA Biotechnology and Cadrenal Therapeutics, Common in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Cadrenal Therapeutics, and MAIA Biotechnology is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on MAIA Biotechnology are associated (or correlated) with Cadrenal Therapeutics,. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Cadrenal Therapeutics, has no effect on the direction of MAIA Biotechnology i.e., MAIA Biotechnology and Cadrenal Therapeutics, go up and down completely randomly.

Pair Corralation between MAIA Biotechnology and Cadrenal Therapeutics,

Given the investment horizon of 90 days MAIA Biotechnology is expected to under-perform the Cadrenal Therapeutics,. In addition to that, MAIA Biotechnology is 1.02 times more volatile than Cadrenal Therapeutics, Common. It trades about -0.05 of its total potential returns per unit of risk. Cadrenal Therapeutics, Common is currently generating about 0.12 per unit of volatility. If you would invest  1,423  in Cadrenal Therapeutics, Common on December 29, 2024 and sell it today you would earn a total of  423.00  from holding Cadrenal Therapeutics, Common or generate 29.73% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

MAIA Biotechnology  vs.  Cadrenal Therapeutics, Common

 Performance 
       Timeline  
MAIA Biotechnology 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days MAIA Biotechnology has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's forward indicators remain somewhat strong which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long term up-swing for the company investors.
Cadrenal Therapeutics, 

Risk-Adjusted Performance

OK

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Cadrenal Therapeutics, Common are ranked lower than 9 (%) of all global equities and portfolios over the last 90 days. In spite of rather uncertain forward-looking signals, Cadrenal Therapeutics, exhibited solid returns over the last few months and may actually be approaching a breakup point.

MAIA Biotechnology and Cadrenal Therapeutics, Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with MAIA Biotechnology and Cadrenal Therapeutics,

The main advantage of trading using opposite MAIA Biotechnology and Cadrenal Therapeutics, positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if MAIA Biotechnology position performs unexpectedly, Cadrenal Therapeutics, can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cadrenal Therapeutics, will offset losses from the drop in Cadrenal Therapeutics,'s long position.
The idea behind MAIA Biotechnology and Cadrenal Therapeutics, Common pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.

Other Complementary Tools

Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets